RES was effective against different molecular subtypes of breast cancer, including luminal A [ER+, PR+/-, Her-2-, low Ki 67]; luminal B [ER+, PR±, Her-2+, high Ki 67], E.R. -, Her-2 + and basal [E.R. -, P.R. -, Her-2-, EGFR + and cytokeratin 5/6+, high Ki 67] [85]. Here, ERBB2 is linked to breast carcinoma.